Published in Blood Weekly, March 30th, 2000
"The aim of this study was to compare fibrinogen binding, inhibition of platelet aggregation and secretory potential of the MAb abciximab (0.5-5 (mu)g/mL) and the peptidomimetic compound SR121-566A (15-250 ng/mL) in vitro in whole blood," wrote U. Klinkhardt and colleagues, University Hospital, Germany.
Klinkhardt et al. published their study in Thrombosis Research ("Differential in vitro effects of the platelet glycoprotein IIb/IIIa inhibitors abixicimab or SR121566A on platelet aggregation, fibrinogen binding and platelet secretory parameters," Thromb Res,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.